Key Highlights

  • Revenues rose to USD 3.2 million from USD 2.9 million a year earlier.
  • Loss was USD 2.28 per share versus an estimated USD 4.80 loss.
  • Selling, general and administrative expense rose to USD 3.7 million from USD 2.0 million.
  • A USD 4.7 million derivative Fair Value change offset USD 2.9 million of interest expense.

Sales Grow While Margin Slips

NexGel, Inc. (NASDAQ:NXGL) reported third-quarter net revenues of USD 3,179 thousand versus USD 2,934 thousand, below the USD 4.19 million estimate in the Earnings data. Cost of revenues was USD 2,054 thousand versus USD 1,691 thousand, leaving gross margin of USD 1,125 thousand versus USD 1,243 thousand.

Selling, general and administrative expense rose to USD 3,664 thousand from USD 1,961 thousand, and the loss from operations was USD 2,539 thousand versus USD 725 thousand.

The nine-month net loss attributable to NexGel stockholders was USD 5,676 thousand versus USD 2,030 thousand, after income attributable to the non-controlling interest in its joint venture of USD 104 thousand versus USD 65 thousand.

Financing Items and Net Loss

Net interest expense was USD 2,935 thousand versus net interest income of USD 10 thousand. A change in fair value of derivative Liability and Warrant modification expense contributed USD 4,656 thousand, a loss on issuance of convertible Debt was USD 402 thousand and other income was USD 127 thousand, bringing total other income, net, to USD 1,446 thousand versus USD 78 thousand.

Net loss was USD 1,093 thousand versus USD 647 thousand, and net loss attributable to NexGel stockholders was USD 1,112 thousand versus USD 653 thousand. Loss per share was USD 2.28 versus USD 1.64, compared with an estimated loss of USD 4.80.

For the nine months, interest expense, net, was USD 5,203 thousand and the loss on issuance of convertible debt was USD 824 thousand, while total other income, net, was USD 431 thousand versus USD 173 thousand.

Nine-Month Results and Business

For the nine months, revenues were USD 9,515 thousand versus USD 8,625 thousand, gross margin was USD 3,294 thousand versus USD 3,690 thousand and the loss from operations was USD 6,003 thousand versus USD 2,138 thousand. Net loss was USD 5,572 thousand versus USD 1,965 thousand, or USD 12.61 per share versus USD 5.23.

The company says it manufactures "high water content, electron beam cross-linked, aqueous polymer hydrogels" used in wound care, medical diagnostics, transdermal drug delivery and cosmetics, and distributes its products as a contract manufacturer.

Balance Sheet and Going Concern

Cash was USD 278 thousand and restricted cash was USD 380 thousand, versus USD 317 thousand and USD 741 thousand at December 31, 2025. Inventory was USD 2,747 thousand, intangibles, net, rose to USD 12,343 thousand from USD 681 thousand and total liabilities were USD 19,233 thousand versus USD 5,570 thousand. The filing states that these conditions raise substantial doubt about the company's ability to continue as a going concern.

Goodwill was USD 1,128 thousand at both dates, and total current Assets were USD 4,936 thousand versus USD 4,338 thousand.

Inventory rose to USD 2,747 thousand from USD 2,111 thousand and Accounts Receivable were USD 804 thousand versus USD 673 thousand. Weighted average basic shares were 487,357 versus 398,565 in the quarter.